Cancer resistance to complement-dependent cytotoxicity (CDC): Problem-oriented research and development
Cancer resistance to complement-dependent cytotoxicity (CDC): Problem-oriented research and development
复制标题
DOI：
10.1016/j.molimm.2009.05.009
复制
发表时间：
2009-09-01
影响因子：
3.6
通讯作者：
Fishelson, Zvi
中科院分区：
文献类型：
--
作者：
Gancz, Dana;Fishelson, Zvi
治疗和临床试验中的抗癌抗体的数量逐渐增加，但由于肿瘤细胞对补体依赖性细胞毒性（CDC）的抗性，其疗效仍然相当有限。介绍了补体在对付肿瘤细胞时所面临的各种防御机制的最新综述。讨论的机制是：膜和分泌的补体调节蛋白、热休克蛋白、细胞外蛋白酶和蛋白激酶、细胞表面唾液酸化和细胞内存活抗裂解信号。针对每种补体抵抗机制描述了预计的治疗策略。可以想象，一旦与使癌细胞对CDC敏感的试剂组合，抗癌抗体的治疗能力将被放大。(C)2009爱思唯尔有限公司版权所有。
The number of anti-cancer antibodies in therapy and in clinical trials is increasing gradually while their curative efficacy remains rather limited due to the resistance of tumor cells to complement-dependent cytotoxicity (CDC). An updated review of the various defense mechanisms complement is confronting when tackling a tumor cell is presented. The mechanisms discussed are: membrane and secreted complement regulatory proteins, heat shock proteins, extracellular proteases and protein kinases, cell surface sialylation and intracellular survival anti-lytic signals. Projected treatment strategies are depicted for each of the complement resistance mechanisms. It is conceivable that the therapeutic capacity of anti-cancer antibodies will be amplified once combined with a reagent that sensitizes the cancer cells to CDC. (C) 2009 Elsevier Ltd. All rights reserved.